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INTRODUCTION
Protease-activated receptor 2 (PAR2), a G protein-coupled receptor (GPCR), is one of four members of the protease-activated receptor family (PAR1-4). Protease-activated receptors have a unique activation mechanism where proteolytic cleavage of the N-terminus is required to reveal a tethered ligand that binds intramolecularly and triggers receptor signaling.
1 Endogenous activation of PAR2 by the protease trypsin 2 exposes the tethered peptide S 36 LIGKV-, which activates several different G protein-mediated signaling pathways including Ca 2+ mobilization. The PAR1 subtype is also activated by trypsin to reveal a distinct tethered ligand S 42 LLFRN-and has an overall 37% sequence identity with PAR2. 3, 4 PARs are involved in a wide range of physiological processes and have been implicated in a number of diseases.
However, the only drug currently targeting the protease-activated GPCRs is the PAR1 antagonist Vorapaxar, which was approved for prevention of thrombosis. 5 The PAR2 subtype has been shown to play roles in pain, migraine, 6, 7 cancer, 8, 9 inflammation 10, 11 , and obesity, 12 as well as metabolic and cardiovascular diseases. 13, 14 For these reasons, PAR2 has attracted great interest as a therapeutic target, but drug development has been challenging due to the unusual activation mechanism and difficulties in identifying small-molecule ligands of the target.
A major breakthrough for structure-based drug design was the recent determination of atomic resolution crystal structures for two PAR subtypes. In 2012, a human PAR1 structure was obtained, 15 which revealed the binding mode of the antagonist vorapaxar. More recently, crystal structures of human PAR2
in complex with two different antagonist ligands (AZ8838 and AZ3451) were determined. 16 The three PAR antagonists, co-crystallized with their corresponding receptors, bind in distinct pockets. AZ3451 is a non-competitive antagonist of PAR2 and acts as a negative allosteric modulator. It occupies a site that is formed by transmembrane (TM) helices 2, 3, and 4 and faces the lipid bilayer whereas the antagonists Vorapaxar (PAR1) and AZ8838 (PAR2) bind in two different pockets within the TM bundle of their receptors. Despite these breakthroughs in structure determination for PARs, the mechanism of activation by the tethered peptide agonists remains unclear. The synthetic hexapeptide corresponding to the last six amino acids of the human PAR2 tethered ligand, SLIGKV, is itself an agonist, 17 indicating that interactions with the cleaved N-terminus are required for receptor activation. Understanding of how peptides and mimetics thereof (e.g. 2-furoyl(2f)-LIGRL-NH2 18 , 2f-LIGRLO-NH2 19 , and GB110 20, 21 ) bind to human PAR2 would facilitate design of small molecule ligands, which could be developed into future therapeutics. However, as reflected by a community-wide assessment of GPCR structure prediction, modeling of peptide binding is very challenging due to the size and flexibility of such ligands and their interactions with the highly variable loop regions. 22 Predictions of agonist recognition by PAR2 have relied on molecular docking to homology models, which has resulted in several different potential binding modes. 23, 24 Even though atomic resolution structures of PAR2 are now available, modeling of the agonist-bound state is limited by that they were determined in an inactive conformation and the identified binding pockets are too small to accommodate any of the available peptide agonists.
Herein, we combined site-directed mutagenesis of human PAR2 with chemical variation of the peptide ligands and computational modeling to predict the binding mode of agonist peptide SLIGKV. In combination with functional assays this approach identified the orthosteric site and key interactions of SLIGKV. Molecular docking calculations guided by the experimental data were used to generate a model of SLIGKV bound to PAR2 consistent with the experimental data. Models obtained via a ligandbased approach, that exploited similarities between synthetic PAR2 ligands and AZ8838, further corroborated the proposed binding mode. Our findings highlight interactions of the human PAR2
receptor that are important for agonist and antagonist design, which was used to guide discovery of a novel, highly potent and selective PAR2 agonist.
RESULTS AND DISCUSSION
Mapping of SLIGKV-PAR2 interactions by mutagenesis. To map interactions between the Nterminal region S 36 LIGKV-and PAR2, we employed an extensive, combinatorial experimental strategy, that introduced point mutations in both receptor and agonist. Previous studies have either focused exclusively on mutagenesis of the TM regions of the receptor, 24 mutagenesis of the tethered ligand,
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mutagenesis of the peptide, 26, 27 or extracellular loop 2 (ECL2). 28, 29 In this work, a total of 24 different point mutations were made in PAR2, and 26 different peptides were evaluated in a Ca 2+ mobilization functional assay. The screened receptor mutants were selected based on the available PAR2 crystal structure and covered the occluded binding site of AZ8838 as well as the neighboring pocket facing the extracellular region. Complementary modifications to the peptide agonist were also designed ( Figure   S1 ). The receptor mutations did not affect receptor expression and only peptides selective for PAR2
were considered ( Figure S2 ). The 1321N1 cell line used in this study has endogenous levels of PAR1 expression. Therefore, the presented lack of activity of these peptides shows that there are no off-target effects, including no PAR1 activity. Competition binding assays using [ 3 H]-GB110 and a selection of peptides from this study were performed on wild type (WT) receptors ( Figure S3 and Table S1 ). In these cases, peptide binding affinity had the same rank order as potency, consistent with previous results using a [ 3 H]propionyl-2fLIGRLO probe and unlabeled SLIGKV, SLIGRL, and 2f-LIGRLO peptides.
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However, determination of binding affinity at mutant PAR2 is challenging due to the lack of an high affinity endogenous agonist that can be labeled. In a recent study characterizing PAR2 receptor 
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The functional calcium potency readout allowed identification of specific receptor-agonist interactions necessary for activation. Nine receptor mutations led to a >10-fold reduction in potency of SLIGKV compared to the effect at WT receptor (Table 1 and Figure 1a ). SLIGKV produced no response at the highest concentrations tested for the D228N ECL2 , H310A 6.58 , and Y323A 7.32 mutants (superscripts represent generic residue numbering system for GPCRs), 32 corresponding to a drop in potency of >342-fold. Although synthetic peptides SLIGKV, SLIGRL (the rat sequence) and mimetics thereof are extensively used to improve understanding of the activation mechanism of the PAR2 receptor, 8, [17] [18] [19] activation by endogenous agonist trypsin was also considered to confirm the relevance of our findings.
WT and mutant PAR2 receptors were screened for trypsin-induced activation ( Figure S4 and Table S2) and identified that modification of the same receptor residues (Y156 3.33 , D228 ECL2 , H310 6.58 , and Y323 7.32 ) had the largest effect irrespective of protease-or peptide-induced activation of PAR2. The residues that upon mutation led to the largest changes in activity were hypothesized to form key interactions with the peptide and provided a starting point for experiment-guided structure-based modeling of its binding mode (Figure 1b ).
Attempts to model SLIGKV bound to PAR2 using the (rigid) receptor conformation represented by the crystal structure indicated that it was not possible to obtain a binding mode consistent with all the experimental data. The mutagenesis data showed that the peptide agonist interacts with residues in two distinct pockets. This is illustrated in Figure 1b , which depicts the two subpockets of the proposed orthosteric site, comprising of an entry point from the extracellular space (cyan) and the occluded AZ8838 binding pocket (red), which is closed off by H227 ECL2 and Y326 7.35 ( Figure S5 ). Therefore, in order to explore potential peptide binding modes, extensive molecular docking to the PAR2 crystal structure (PDB code 5NDD) 16 was performed with AutoDock. 33 To facilitate accommodation of the agonist, several of the residues identified as important by mutagenesis (H310 6.58 , Y323 7.32 , and Y326 7.35 ) were considered flexible during the docking simulations. SLIGKV showed a modest decrease in potency when H227 ECL2 and Y311 6.59 were mutated to Ala (3-and 6-fold respectively, Table 1 ), but including flexibility for these side chains allowed the peptide to access both pockets of the proposed orthosteric site. In addition, Q233 ECL2 was also considered flexible to enlarge the entrance route for SLIGKV. A total of 10,000 models, each with a unique receptor and ligand conformation, were generated. The resulting binding modes ( Figure 2 ) were analyzed by hierarchical clustering to identify those that agreed with the experimental data. An overview of the structure-based modeling strategy is shown in Figure S6 .
A first cluster analysis of the peptide conformations was performed by applying an RMSD threshold of 8 Å and clusters that captured the expected overall binding mode of the peptide were identified. As the SLIGKV peptide is endogenously tethered to the receptor, solutions that did not have the C-terminus facing the extracellular surface were excluded. This criterion reduced the number of models from 10,000 to a single cluster of solutions containing 4625 structures ( Figure 2 ).
Interactions with D228 ECL2 and Y82 1.39 anchor SLIGKV in the binding site. D228 ECL2 is part of the AZ8838 binding pocket (Figure 1b ) and forms a hydrogen bond to the imidazole ring of the antagonist in the crystal structure ( Figure S5 ). 16 D228 ECL2 is conserved in all four PARs and has been reported as a key interacting partner in PAR1 activation. 15, 31 As it is the only buried negatively charged residue facing the predicted orthosteric site, we hypothesized that D228 forms a salt bridge with the N-terminal charge of SLIGKV. The D228A ECL2 mutation led to a large decrease in potency (124-fold), suggesting that D228 ECL2 is a key interacting partner of SLIGKV (Table 2) . Similarly, the D228N ECL2 mutation, lacking the side chain charge, but maintaining the size of the residue lost >342-fold in activity, supporting that the interaction with the charge is important. The significance of interactions with D228 . This criterion reduced the number of candidate models to 611 ( Figure 2 ). AZ8838 also forms a hydrogen bond to Y82 1.39 in the crystal structure ( Figure S5 ), which provided a potential candidate to interact with the hydroxyl group of the N-terminal serine. Removing the side chain hydrogen bond donor of the agonist (ALIGKV) led to a 9-fold decrease in potency compared to SLIGKV ( Hydrophobic side chains in position two and three of SLIGKV are important for potency. Leucine and isoleucine at position two and three of the peptide agonist were modified to assess the size of the pockets available to these residues (Table 3 and Figure 3a ). Alanine substitution of the leucine in position two of SLIGKV resulted in loss of functional activity at all concentrations tested. In contrast, increasing the size of the side chain to a cyclohexylalanine (Cha) improved potency by 2-fold. Larger variants of the side chain such as homophenylalanine (Hph) and indanylglycine (Igl) resulted in a loss of potency (27-and 18-fold, respectively) ( Figure 3a ). The importance of the leucine residue was further exemplified by alanine substitution of the last four amino acids (SLAAAA), which produced only a 61-fold drop in potency compared to SLIGKV (Table 3) . Consistent with an extensive study of PAR1 and PAR2 peptide agonists, 26 we found that leucine at position two of SLIGKV was vital for PAR2 activation and specificity. Some designed peptides e.g. SFIGKV, SWIGKV, and S[Phe(3,4-diChloro)]IGKV, were excluded as they showed a response in the parental cell line and were suspected of having PAR1 activity. At position three, a bulky hydrophobic side chain was also found to be favorable, as alanine substitution caused a 17-fold loss of potency. A small increase in side chain size to cyclohexylglycine (Chg) or methionine improved (3-fold) and maintained potency, respectively.
However, as in the case of position two, the pocket size was limited. Tryptophan caused a 43-fold reduction in potency and 2-napthylalanine (2Nal) and O-tert-butyl threonine (Thr(tBu)) substitutions led to >342-fold loss of activity ( Figure 3a) . The data therefore supported that both positions two and three of SLIGKV were buried in the orthosteric site. This result was reproduced by the selected cluster of docking solutions, but among the 611 models different hydrophobic pockets were explored by the leucine and isoleucine residues.
To investigate which subpockets of the orthosteric site accommodate positions two and three of SLIGKV, the modified peptides S[Cha]IGKV and SL[Chg]GKV were screened against PAR2 mutants (Table 4 ). The fold change in potency of each peptide compared to SLIGKV was calculated at each receptor and the receptor mutations that caused the largest changes are shown in Figure 3b . The most striking results from these experiments were those obtained for the Y326A Figure S7 . No corresponding strong correlations were identified for SL[Chg]GKV at the screened mutants ( Figure 3b ). This could be explained as the pocket for the third residue of SLIGKV is likely located closer to the extracellular surface and ECL2 of the receptor and could hence be more flexible than those occupied by the first two residues. The ensemble of 611 remaining models was clustered based on the positions of the leucine and isoleucine residues of SLIGKV using an RMSD threshold of 4 Å ( Figure S6 ). A total of 18 clusters were obtained and these poses were visually inspected and filtered primarily based on interactions with Y323 7.32 and Y326 7.35 ( Figure 4 ). The fifth cluster with 64 models showed placement of the leucine in a pocket composed of Interaction with E232 ECL2 at the receptor surface. If E232 ECL2 in ECL2 was mutated to an alanine (E232A ECL2 ) or if only the charge was removed (E232Q ECL2 ), there was a 7 and 8-fold loss in SLIGKV potency respectively (Table 5) . A larger 16-fold change in SLIGKV potency was observed with charge reversal to a positively charged arginine (E232R ECL2 /N222Q ECL2 , Table 5 , Figure 5a and 5c). The E232R ECL2 /N222Q ECL2 mutant was already available from a prior study and the single N222Q ECL2 mutation, located in ECL2, did not have a significant effect on SLIGRL potency in calcium signaling assays. 16 A charge reversed peptide (SLIGEV) displayed the opposite activity pattern to SLIGKV.
SLIGEV had the lowest potency at WT and the neutral mutants (E232A ECL2 and E232Q ECL2 ), whereas it was most potent on the E232R ECL2 /N222Q ECL2 mutant receptor, as salt bridge formation was then possible (Table 5 , Figure 5b and 5c). Removal of the lysine charge in the peptide agonist (SLIGAV)
showed smaller effects at the E232 ECL2 mutants and the pattern of regaining potency was not observed with the E232R ECL2 /N222Q ECL2 mutant (Table 5 , Figure 5c ). The mutagenesis data therefore suggested that there is a salt bridge between the lysine of the peptide and E232 ECL2 . A previous study also highlighted the importance of E232 ECL2 in peptide activation of the rat PAR2 receptor. 28 Furthermore, a similar charge reversal experiment for PAR1 reached the same conclusion that SFLLEN gained back activity on the corresponding (E260R ECL2 ) mutant receptor compared to the SFLLRN peptide at WT.
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No charge-charge interactions between the lysine of the peptide and E232 ECL2 were found among the remaining 64 models of PAR2-SLIGKV. This appeared to be due to the conformation of ECL2, which oriented the side chain away from the entry point of the proposed orthosteric site. To explore if this interaction could be formed, refinement was performed for a representative model using MODELLER, 
. To construct a shape-based overlay with SLIGKV using this ligand-based approach, a conformational search for GB88 was performed as it had the lowest number of rotatable bonds among the ligands, which reduced the number of potential poses to consider. The resulting ensemble was filtered using the program ROCS 36 to identify conformations that matched the shape of AZ8838 and carbon atoms placed in positions hypothesized to be occupied by positions two and three of SLIGKV in the binding site. An overlay of the best fitting pose of GB88 to the PAR2 crystal structure (PDB code AZ8838-and the agonist-bound complexes. The first four residues of SLIGKV and 2f-LIGRLO could also be placed in this model without clashes by using a shape-based alignment to the predicted binding conformation of GB88. The heterocycles of GB88 and 2f-LIGRLO overlapped with both the imidazole group of AZ8838 and the N-terminal part of SLIGKV in our model.
Analysis of the ligand-based shape alignment in relation to the PAR2 complex structure with AZ8838 Figure 9 .
In several previous studies, prediction of ligand binding modes for PAR2 ligands was constrained to using homology models based on templates with low sequence identity, e.g. bovine rhodopsin 23, 24, 39 and human ORL-1 (nociceptin/orphanin FQ receptor) 23, 24, 40 withTM sequence identities of 21% and 29%, respectively. Homology models based on these templates will have large errors in the ECL2 and relative orientation of TM helix 7, making it difficult to obtain an accurate structure of the binding site.
The difficulties in obtaining a consistent binding mode for PAR2 agonists has been highlighted by a number of studies that used homology models based on templates with low sequence identity.
24, 39, 40
Suen et al. 24 recently identified residues important for 2f-LIGRL-NH2 binding based on mutagenesis (e.g Y82 whereas these residues appear to be located in distinct pockets in the homology model based on rhodopsin. 24 Due to differences in ECL2 of the rhodopsin-based model, D228 ECL2 is facing into the extracellular space and so was previously predicted to interact with the arginine residue of 2f-LIGRL-NH2 (equivalent to the lysine of SLIGKV). In addition, the C-terminal leucine of 2f-LIGRL-NH2
(corresponding to the valine in SLIGKV) was predicted to interact with Y82 1.39 whereas we position the N-terminal moiety in this region. The former option was obtained as one of our docking solutions in the PAR2 structure, but was discarded because of the constraint that the C-terminus of the peptide must extend to the extracellular space to be consistent with the endogenous tethered ligand. The PAR1 crystal structure provided a better template for PAR2 homology modeling, 24 based on high TM sequence identity (44%), but the binding site conformation may not be relevant for PAR2 as it was determined in complex with a PAR1 selective antagonist (vorapaxar). In addition, a homology model based on PAR1 primarily differs from the PAR2 crystal structure in ECL2 and TM helices 5 and 6. Therefore, even though the PAR2 crystal structure was also determined in an inactive conformation, 16 it represented an improved starting point for modeling. The structure brought the occluded binding pocket occupied by AZ8838 to our attention and demonstrated that D228 ECL2 could form key interactions in this region.
However, it should be emphasized that the crystal structure alone provided few clues on the interactions with SLIGKV. The constraints derived from the mutations and modified peptides were crucial in the modeling process as docking poses were selected based on these experiments.
In light of the new PAR2 crystal structures, an extensive array of mutagenesis data generated for this GPCR has been placed into structural context for the first time. In support of the previous studies on modification of peptide agonists, we report the need for a charged or heterocyclic moiety at the amino terminus 17, 41 , the importance of the leucine at position two, 27 and improved potencies for larger hydrophobic side chains (e.g. Cha and Chg) at positions two and three. 26 Our experimental data also align well with other receptor mutagenesis studies which are summarized in Figure S13 and 
CONCLUSIONS
Drug discovery for PARs has been hampered by the challenges involved in development of ligands.
Access to structural information and understanding of the interactions responsible for receptor activation provides opportunities for rational drug design. Our model of agonist-bound PAR2 shows that SLIGKV binds in an extended conformation, occupying two pockets identified in the inactive crystal structure.
The same binding mode was maintained in models of synthetic agonists, which supports that interactions in both sites are necessary for receptor activation and guided design of new PAR2 agonists.
This also revealed the structural basis of antagonism by AZ8838, highlighting that the antagonist blocks access to the region of the orthosteric site that recognizes the N-terminus of SLIGKV. Antagonists may be obtained by targeting the AZ8838 pocket, but as optimization of potency may be challenging due to its limited size, the novel orthosteric site identified in this work provides an attractive alternative. The model could be useful in future virtual screening campaigns for novel PAR2 antagonists and agonists and in design of experiments focused on understanding the structural basis of receptor activation. The combined experimental and computational approach to characterize agonist binding modes can be extended to study the many other GPCRs that recognize peptides or proteins.
METHODS
Materials. PAR2 was expressed in the recombinant 1321N1 cell line (ATCC). Plasmids containing PAR2 with/without single point mutations were purchased from ThermoFisher. SLIGKV and mutant peptide agonists (2D structures can be found in Figure S1 ) were purchased from ThermoFisher except SL[OtBu]GKV and S[Phe(3,4-diChloro)]IGKV, which were purchased from Chinese Peptide Company, China. All peptides had a free amino terminus and were amidated at the C-terminus. All peptides were >95% pure. Small molecule GB110 was synthesized as in Cheng et al. Calcium mobilization assay. PAR2-induced calcium release was monitored using the Screen Quest™ with NME and protonated at physiological pH using PyMol. 47 Structures of GB88 and GB110 were built in Marvin 48 and low energy conformers were obtained using the cxcalc tool. A total of 500 conformers were generated using the hyperfine option and optimization limit set to 2.
An implemented version of AutoDock 33 (Release 4.2.6) was compiled to handle >32 rotatable bonds.
Receptor flexibility was accounted for by considering multiple side chain rotamers for H310 6 files were prepared through the AutoDockTools (ADT) package 33 using a grid of 59x67x51 points in the xyz dimension with a spacing of 0.375 Å. AutoGrid4 was used to generate grid maps. The Lamarckian genetic algorithm (LGA) was employed: the global optimization started with a population of 300 individuals; a maximum of 10 million energy evaluations, 27,000 generations and 100 runs were set.
100 independent screens were performed to collect a total of 10,000 poses.
Cluster analysis. The results from AutoDock were collected to perform a hierarchical cluster analysis for the 10,000 poses. Clustering was performed by means of the Clusterizer 1. residues. A total of 25 models were generated, sorted by DOPE score and visually inspected.
Ligand-based modeling. and the resins were washed with DMF (55 mL) followed by MeOH (3×5 mL). Cleavage from resin was carried out using pre-cooled solution of TFA/Water/TiPS (95:2.5:2.5, ~5 mL) and for 1 h 20 min.
The cleavage mixtures were concentrated and precipitated from DEE, centrifuged, and the ether layers were decantated off. The precipitates were redissolved in water/acetonitrile/acetic acid (68:30:2) and lyophilized to obtain the crude peptides. The crude peptides were purified by HPLC and pure fraction was lyophilized with 2% AcOH twice to obtain the modified peptides as TFA salts. -2,17-dimethyl-5,8,11,14- Table 1 . Asterisks highlight the residues identified as important in SLIGKV-induced activation of PAR2. (b) Crystal structure of PAR2 (PDB code 5NDD) 16 with side chains of key residues shown as sticks. The predicted orthosteric binding site is depicted as a surface mesh, encompassing an entry point from the extracellular space (cyan) and the AZ8838 binding site (red). Residues have been color coordinated based on their spatial arrangement. Figure 2 . Filtering of PAR2-SLIGKV complexes obtained from molecular docking based on expected placement of N-and C-termini. The 10,000 generated models were clustered and the best docked poses from the four largest clusters are shown. Cluster 1 was selected as the position of the C-terminal was facing the extracellular surface, which is compatible with a tethered endogenous peptide. Then, the models from Cluster 1 with a distance >3.5 Å between the serine α-amino group (-NH3 + ) nitrogen and one of the two carboxylate oxygens of D228 ECL2 were discarded. Residues have been color-coordinated based on their spatial arrangement. Blue spheres represent the α-amino group nitrogen of the serine in SLIGKV. Figure S1 and potency data are in Tables 3 and 4 . PAR2 ligands SLIGKV, 2f-LIGRLO, GB110, and GB88 display similar pharmacophoric groups with a polar or heterocyclic motif in the first position (orange) and a hydrophobic residue in the second (blue) and third (green) position. The models of SLIGKV and GB88 suggested that the first position was overlapping with the imidazole moiety of the small molecule antagonist AZ8838 and that none of the agonists exploited the pocket occupied by the 4-fluoro-2-propylphenyl moiety. New compounds were designed based on the SLIGKV sequence that probed a lipophilic extension of the agonist SLIGKV (yellow). 3.96±0.04 < 3.5 < 3.5 D228N ECL2 < 3.5 < 3.5 < 3.5 
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